ES2071827T3 - Producto farmaceutico para el tratamiento de la sepsis. - Google Patents

Producto farmaceutico para el tratamiento de la sepsis.

Info

Publication number
ES2071827T3
ES2071827T3 ES90913206T ES90913206T ES2071827T3 ES 2071827 T3 ES2071827 T3 ES 2071827T3 ES 90913206 T ES90913206 T ES 90913206T ES 90913206 T ES90913206 T ES 90913206T ES 2071827 T3 ES2071827 T3 ES 2071827T3
Authority
ES
Spain
Prior art keywords
antibody
sepsis
specific
lipopolisacaride
lps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90913206T
Other languages
English (en)
Inventor
Mark William Bodmer
Steven Michael Rhode Isla Opal
Alan S C O Walter Reed A Cross
Jerald C O Walter Reed Sadoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd filed Critical Celltech Ltd
Application granted granted Critical
Publication of ES2071827T3 publication Critical patent/ES2071827T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Biological Wastes In General (AREA)
  • Finger-Pressure Massage (AREA)
  • Ink Jet (AREA)

Abstract

SE PRESENTAN UN ANTICUERPO AL FACTOR-(ALFA) DE LA NECROSIS DE TUMORES (ANTI-TNF) Y UN ANTICUERPO AL LIPOPOLISACARIDO BACTERIANO (ANTI-LPS) UTILIZADOS JUNTO CON UN MODELO DE RATA NEUTROPENICA DE LA SEPSIS PARA AUMENTAR LA SUPERVIVENCIA DE LAS RATAS RESPECTO A CUALQUIERA DE LOS ANTICUERPOS UTILIZADO POR SI SOLO. LOS PRODUCTOS FARMACEUTICOS QUE INCLUYEN CADA UNO DE LOS COMPONENTES SON POR TANTO UTILES PARA LA TERAPIA DE LA SEPSIS. EL ANTICUERPO ANTI-LPS INCLUIDO PUEDE SER ESPECIFICO PARA LA CADENA ESPECIFICA O DE UN LIPOPOLISACARIDO BACTERIANO PARTICULAR (ANTICUERPO ESPECIFICO DE UN SEROTIPO) PERO PREFERENTEMENTE RECONOCE EL NUCLEO GLICOLIPIDO DEL LIPOPOLISACARIDO.
ES90913206T 1989-08-10 1990-08-10 Producto farmaceutico para el tratamiento de la sepsis. Expired - Lifetime ES2071827T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898918232A GB8918232D0 (en) 1989-08-10 1989-08-10 Pharmaceutical product for the treatment of septic shock

Publications (1)

Publication Number Publication Date
ES2071827T3 true ES2071827T3 (es) 1995-07-01

Family

ID=10661418

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90913206T Expired - Lifetime ES2071827T3 (es) 1989-08-10 1990-08-10 Producto farmaceutico para el tratamiento de la sepsis.

Country Status (10)

Country Link
EP (1) EP0486609B1 (es)
JP (1) JPH05505592A (es)
AT (1) ATE119043T1 (es)
AU (2) AU651320B2 (es)
DE (1) DE69017455T2 (es)
DK (1) DK0486609T3 (es)
ES (1) ES2071827T3 (es)
GB (2) GB8918232D0 (es)
WO (1) WO1991001755A1 (es)
ZA (1) ZA906345B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6852594A (en) * 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
WO1995003057A1 (en) * 1993-07-20 1995-02-02 Chugai Seiyaku Kabushiki Kaisha Endotoxin neutralizer
AU2356095A (en) * 1994-04-20 1995-11-29 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
RU2199115C2 (ru) * 2000-07-10 2003-02-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ прогноза развития инфекции и тяжелых инфекционных осложнений у больных гемобластозами на программной полихимиотерапии
CA2431206C (en) * 2000-12-08 2009-09-01 Takeda Chemical Industries, Ltd. Combination drugs containing anti-sepsis cycloalkene compound
WO2006063150A2 (en) 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
EP0374510B1 (en) * 1988-12-19 1997-01-15 American Cyanamid Company Products for the treatment of endotoxic shock in a mammal

Also Published As

Publication number Publication date
WO1991001755A1 (en) 1991-02-21
GB2251187A (en) 1992-07-01
ATE119043T1 (de) 1995-03-15
GB2251187B (en) 1993-06-23
GB9202615D0 (en) 1992-03-25
GB8918232D0 (en) 1989-09-20
DE69017455D1 (de) 1995-04-06
AU651320B2 (en) 1994-07-21
ZA906345B (en) 1992-04-29
JPH05505592A (ja) 1993-08-19
AU6350090A (en) 1991-03-11
EP0486609B1 (en) 1995-03-01
AU7590694A (en) 1995-01-27
DE69017455T2 (de) 1995-06-29
EP0486609A1 (en) 1992-05-27
DK0486609T3 (da) 1995-05-08

Similar Documents

Publication Publication Date Title
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
IS2845A7 (is) Forefni til framleiðslu á omeprazole
DE3883803D1 (de) Monoklonale Antikörper gegen melanoma-assoziierte Antigene, Hybridzellinien, die diese Antikörper produzieren, und ihre Verwendung.
NO872988L (no) Pattedyr-interleukin-4.
NO890715D0 (no) Fremgangsmaate ved preservering av epitelsjikt dyrket in vitro.
BR0015620A (pt) Produto de emulsão de carne
DK1115840T3 (da) Afstamningsspecifikke celler og progenitorceller
ES2124250T3 (es) Anticuerpo especifico para un antigeno tumoral.
DE69133332D1 (de) Menschliche hematopoietische Stammzellen
ATE195875T1 (de) Spezifische modulationen des immunsystems
ZA838072B (en) Beta-carbolines,process for their production and pharmaceutical preparations containing them
BG35465A3 (en) Method for preparing derivatives of 1-(cyclohexyl)-4-aryl-4- piperidine carbonic acid
ES2071827T3 (es) Producto farmaceutico para el tratamiento de la sepsis.
FI102191B1 (fi) Menetelmä 3-des-hydroksikystatiini C:n tuottamiseksi ja menetelmässä käytettävä DNA-sekvenssi
BG41137A3 (bg) Метод за получаване на днк преносен вектор,предназначен за поддържане и репликация на дезоксинуклеотидна последо- вателност,кодираща човешки препроинсулин
DE3855080D1 (de) Synoviale phospholipasen
DE69232945D1 (de) BLUTPLAETTCHEN-GPIIIa P1A1 und -P1A2-EPITOPE, IHRE HERSTELLUNG UND VERWENDUNG
DK16087A (da) Mastitis-vaccine
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
ES2064336T3 (es) Procedimiento para la preparacion de proteinas.
BG47345A3 (en) Method for preparing of dialkyloxalacetates
JPS57181695A (en) Production of heterophile antibody
JPS54114971A (en) Continuous environmental unit for semiconductor
SU1565021A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к вирусу ящура 0-01618

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 486609

Country of ref document: ES